Literature DB >> 12167790

Preoperative evidence of circulating tumor cells by means of reverse transcriptase-polymerase chain reaction for carcinoembryonic antigen messenger RNA is an independent predictor of survival in non-small cell lung cancer: a prospective study.

Jun-ichi Yamashita1, Akinobu Matsuo, Yuji Kurusu, Tetsushi Saishoji, Naoko Hayashi, Michio Ogawa.   

Abstract

OBJECTIVE: We conducted a prospective study of 103 consecutive patients with non-small cell lung cancer who underwent a curative lobectomy to test whether circulating tumor cells detected in the peripheral blood by means of reverse transcriptase-polymerase chain reaction of carcinoembryonic antigen messenger RNA is a prognostic indicator independent of tumor stage in patients with non-small cell lung cancer.
METHODS: We assayed for carcinoembryonic antigen messenger RNA by means of reverse transcriptase-polymerase chain reaction in peripheral blood taken at the time of diagnosis before an operation and again 2 to 3 weeks after an operation from patients with non-small cell lung cancer who underwent a curative lobectomy between March 1996 and April 1998. We analyzed the prognostic value of carcinoembryonic antigen messenger RNA expression in the patients with non-small cell lung cancer in a univariate and multivariate manner.
RESULTS: Patients with carcinoembryonic antigen messenger RNA in the preoperative blood samples had a poor survival when compared with those without carcinoembryonic antigen messenger RNA. Of these patients, the worst survival was seen in those with carcinoembryonic antigen messenger RNA in the postoperative blood samples. The multivariate stepwise analysis selected the preoperative carcinoembryonic antigen messenger RNA expression (P =.0004; relative risk, 0.21) and the pathologic stage of disease (P =.0002; relative risk, 1.43) as the independent prognostic factors for survival.
CONCLUSIONS: The molecular detection of carcinoembryonic antigen messenger RNA in the preoperative peripheral blood is an independent prognostic factor in patients with non-small cell lung cancer who undergo a curative operation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12167790     DOI: 10.1067/mtc.2002.124370

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  25 in total

1.  Enhancing antitumor immunity perioperatively: a matter of timing, cooperation, and specificity.

Authors:  Jeffrey L Curtis; Antonello Punturieri
Journal:  Am J Respir Cell Mol Biol       Date:  2003-05       Impact factor: 6.914

Review 2.  Clinical utility of circulating tumour cell detection in non-small-cell lung cancer.

Authors:  Alberto Fusi; Robert Metcalf; Matthew Krebs; Caroline Dive; Fiona Blackhall
Journal:  Curr Treat Options Oncol       Date:  2013-12

Review 3.  Circulating tumor cells (CTCs) in lung cancer: current status and future perspectives.

Authors:  Fumihiro Tanaka; Kazue Yoneda; Seiki Hasegawa
Journal:  Lung Cancer (Auckl)       Date:  2010-07-03

Review 4.  Circulating tumor cells versus circulating tumor DNA in lung cancer-which one will win?

Authors:  Silvia Calabuig-Fariñas; Eloísa Jantus-Lewintre; Alejandro Herreros-Pomares; Carlos Camps
Journal:  Transl Lung Cancer Res       Date:  2016-10

Review 5.  Clinical utility of circulating tumor cells in patients with non-small-cell lung cancer.

Authors:  Marianna Gallo; Antonella De Luca; Monica Rosaria Maiello; Amelia D'Alessio; Claudia Esposito; Nicoletta Chicchinelli; Laura Forgione; Maria Carmela Piccirillo; Gaetano Rocco; Alessandro Morabito; Gerardo Botti; Nicola Normanno
Journal:  Transl Lung Cancer Res       Date:  2017-08

6.  Perioperative circulating tumor cells in surgical patients with non-small cell lung cancer: does surgical manipulation dislodge cancer cells thus allowing them to pass into the peripheral blood?

Authors:  Noriyoshi Sawabata; Soichiro Funaki; Takeru Hyakutake; Yasushi Shintani; Ayako Fujiwara; Meinoshin Okumura
Journal:  Surg Today       Date:  2016-03-07       Impact factor: 2.549

7.  The effects of anesthetics on tumor progression.

Authors:  Lifang Mao; Suizhen Lin; Jun Lin
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2013-03-08

8.  Lunx is a superior molecular marker for detection of non-small cell lung cancer in peripheral blood [corrected].

Authors:  Michael Mitas; Loretta Hoover; Gerard Silvestri; Carolyn Reed; Mark Green; Andrew T Turrisi; Carol Sherman; Kaidi Mikhitarian; David J Cole; Mark I Block; William E Gillanders
Journal:  J Mol Diagn       Date:  2003-11       Impact factor: 5.568

Review 9.  Cancer micrometastases.

Authors:  Klaus Pantel; Catherine Alix-Panabières; Sabine Riethdorf
Journal:  Nat Rev Clin Oncol       Date:  2009-06       Impact factor: 66.675

10.  Prognostic value of EpCAM/MUC1 mRNA-positive cells in non-small cell lung cancer patients.

Authors:  Wen-Fang Zhu; Jian Li; Li-Chao Yu; Yian Wu; Xin-Ping Tang; Yi-Ming Hu; Yong-Chang Chen
Journal:  Tumour Biol       Date:  2013-09-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.